Biotinylated Human B7-2 / CD86 Protein, Fc,Avitag?, premium grade
分子別名(Synonym)
CD86,B7-2,B70,CD28LG2,LAB72,MGC34413
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Biotinylated Human B7-2, Fc,Avitag, premium grade (CD6-H82F5) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # P42081).
Predicted N-terminus: Leu 26
該產(chǎn)品是在我們嚴(yán)格的質(zhì)量控制體系下生產(chǎn)的,該體系包含一套全面的測試,包括無菌和內(nèi)毒素測試。在早期臨床前階段,產(chǎn)品性能經(jīng)過仔細(xì)驗(yàn)證和測試,以確保其與細(xì)胞培養(yǎng)用途或任何其他應(yīng)用的兼容性。當(dāng)準(zhǔn)備過渡到后期臨床階段時,我們還提供定制的GMP蛋白質(zhì)服務(wù),以滿足您的需求。我們將與您合作,根據(jù)您的要求定制和開發(fā)GMP級產(chǎn)品,該產(chǎn)品也符合細(xì)胞療法細(xì)胞制造中使用的原材料和輔助材料的要求。
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 53.8 kDa. The protein migrates as 66-90 kDa under reducing (R) condition, and 130-150 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
標(biāo)記(Labeling)
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
無菌(Sterility)
Negative
支原體(Mycoplasma)
Negative.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
分化簇86(CD86)也稱為B淋巴細(xì)胞活化抗原B7-2,是一種I型膜蛋白,是免疫球蛋白超家族的成員,在交叉樹突細(xì)胞、朗格罕斯細(xì)胞、外周血樹突細(xì)胞、記憶B細(xì)胞和生發(fā)中心B細(xì)胞上組成型表達(dá)。此外,B72在單核細(xì)胞上的表達(dá)水平較低,可以通過干擾素γ上調(diào)。CD86是T細(xì)胞表面兩種不同蛋白質(zhì)的配體:CD28(用于自動調(diào)節(jié)和細(xì)胞間結(jié)合)和CTLA-4(用于減弱調(diào)節(jié)和細(xì)胞分離)。CD86與CD80協(xié)同作用以激活T細(xì)胞。最近的研究表明,B7-2促進(jìn)了成熟APC庫的產(chǎn)生,并促進(jìn)了APC的功能和存活。此外,B7蛋白還通過激活巨噬細(xì)胞中的NF-κB信號通路參與先天免疫反應(yīng)。因此,CD86被視為免疫治療的有前景的候選者?;羝娼鹆馨土龌颊叩?/span>CD86+巨噬細(xì)胞是一線治療潛在無反應(yīng)的獨(dú)立標(biāo)志物。
關(guān)鍵字: B7-2;B7-2蛋白;CD86蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。